Lenacapavir has shown strong results in HIV prevention and has been recommended by the WHO, but MSF says licensing, pricing and supply arrangements could limit access in several countries and humanitarian settings.
2,000participants
The 2024 lenacapavir clinical trial involved more than 2,000 young women.